- NCIt
- C4951
Loading cancer entity…
Loading cancer entity…
Clinical trials
26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT00679354 | Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 1, 2018 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2024source: clinicaltrials
| NCT01462695 |
| Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma |
| completed |
| Phase 2 |
| 30 |
| National Cancer Institute (NCI)NIH |
| 3 |
| Aug 27, 2015 |
| clinicaltrials |
| NCT00070525 | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |